液体活检在结直肠癌领域的研究及应用现状

doi:10.11904/j.issn.1002-3070.2018.04.017

摘要/Abstract

摘要： 近年来,液体活检作为新兴的分子诊断技术,具有实时性和可重复性,在临床工作中发挥越来越重要的作用。液体活检主要通过无创方法收集患者体液,检测分析循环肿瘤细胞、循环肿瘤DNA、外泌体等生物学标志物。本文将从液体活检的生物学基础及其在结直肠癌临床应用方面进行综述。

关键词: 液体活检, 循环肿瘤细胞, 循环肿瘤DNA, 外泌体, 结直肠癌

Abstract: In recent years,liquid biopsy has emerged as a new molecular diagnostic technology that is real-time and reproducible,and plays an increasingly important role in clinical practice.Liquid biopsy mainly collects the body fluids through non-invasive approaches,and analyzes biological markers such as circulating tumor cells,circulating tumor DNA and exosomes.This article will review the biological basis of liquid biopsy and its clinical application in colorectal cancer.

Key words: Liquid biopsy, CTC, ctDNA, Exosomes, Colorectal cancer

中图分类号:

R735.3⁺4

崔雪阳, 邢承忠. 液体活检在结直肠癌领域的研究及应用现状[J]. 实用肿瘤学杂志, 2018, 32(4): 367-370.

CUI Xueyang,XING Chengzhong. The research and application of liquid biopsy in the field of colorectal cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 367-370.

参考文献

1 Siravegna G,Mussolin B,Buscarino M,et al.Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients[J].Nat Med,2015,21(7):795-801.
2 Morelli MP,Overman MJ,Dasari A,et al.Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment[J].Ann Oncol,2015,26(4):731-736.
3 Jr L AD,Williams R,Wu J,et al.The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers[J].Nature,2012,486(7404):537-540.
4 Reckamp KL,Melnikova VO,Karlovich C,et al.A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma[J].J Thorac Oncol,2016,11(10):1690-1700.
5 De Mattos-Arruda L,Mayor R,Ng CK,et al.Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma[J].Nat Commun,2015,6:8839.
6 Wang Y,Springer S,Mulvey CL,et al.Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas[J].Sci Transl Med,2015,7(293):293.
7 Krebs MG,Metcalf RL,Carter L,et al.Molecular analysis of circulating tumour cells-biology and biomarkers[J].Nat Rev Clin Oncol,2014,11(3):129-144.
8 Alixpanabières C,Schwarzenbach H,Pantel K.Circulating tumor cells and circulating tumor DNA[J].Annu Rev Med,2012,63(1):199-215.
9 Alixpanabières C,Pantel K.Challenges in circulating tumour cell research[J].Nat Rev Cancer,2014,14(9):623-631.
10 Schindlbeck C,Andergassen U,Jueckstock J,et al.Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients:properties,enrichment,and potential targets[J].J Cancer Res Clin Oncol,2016,142(9):1-13.
11 Alixpanabières C,Pantel K.Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J].Cancer Discov,2016,6(5):479-491.
12 Leary RJ,Sausen M,Kinde I,et al.Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing[J].Sci Transl Med,2012,4(162):162ra154.
13 Zhang J,Li S,Li L,et al.Exosome and exosomal microRNA:trafficking,sorting,and function[J].Genomics Proteomics Bioinformatics,2015,13(1):17-24.
14 Kahlert C,Kalluri R.Exosomes in tumor microenvironment influence cancer progression and metastasis[J].J Mol Med,2013,91(4):431-437.
15 Best MG,Nik S,Irsan K,et al.RNA-seq of tumor-educated platelets enables blood-based pan-cancer,multiclass,and molecular pathway cancer diagnostics[J].Cancer Cell,2015,28(5):666-676.
16 Cyhaniuk A,Coombes ME.Longitudinal adherence to colorectal cancer screening guidelines[J].Am J Manag Care,2016,22(2):105-111.
17 Bettegowda C,Sausen M,Leary RJ,et al.Detection of circulating tumor DNA in early-and late-stage human malignancies[J].Sci Transl Med,2014,6(224):224ra24.
18 Cohen JD,Li L,Wang Y,et al.Detection and localization of surgically resectable cancers with a multi-analyte blood test[J].Science,2018,359(6378):926-930.
19 Ogata-Kawata H,Izumiya M,Kurioka D,et al.Circulating exosomal microRNAs as biomarkers of colon cancer[J].PLoS One,2014,9(4):e92921.
20 Yoshioka Y,Kosaka N,Konishi Y,et al.Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen[J].Nat Commun,2014,5(4):3591-3598.
21 Tsai WS,Chen JS,Shao HJ,et al.Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients[J].Sci Rep,2016,6:24517.
22 Seeberg LT,Waage A,Brunborg C,et al.Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival[J].Ann Surg,2015,261(1):164-171.
23 Reinert T,Sch?ler LV,Thomsen R,et al.Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery[J].Gut,2016,65(4):625-634.
24 Matsumura T,Sugimachi K,Iinuma H,et al.Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer[J].Br J Cancer,2015,113(2):275-281.
25 Hoshino A,Costa-Silva B,Shen TL,et al.Tumour exosome integrins determine organotropic metastasis[J].Nature,2015,527(7578):329-335.
26 Senfter D,Holzner S,Kalipciyan M,et al.Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro[J].Hum Mol Genet,2015,24(13):3689-3698.
27 Tie J,Wang Y,Tomasetti C,et al.Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer[J].Sci Transl Med,2017,11(2):117-118.
28 Magni E,Botteri E,Ravenda PS,et al.Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery[J].Int J Colorectal Dis,2014,29(9):1053-1059.
29 Schmidt MA,Förtsch C,Schmidt M,et al.Circulating regulatory T cells of cancer patients receiving radiochemotherapy may be useful to individualize cancer treatment[J].Radiother Oncol,2012,104(1):131-138.
30 Cha DJ,Franklin JL,Dou Y,et al.KRAS-dependent sorting of miRNA to exosomes[J].Elife,2015,4:e07197.

[1]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[2]	佟广海, 田洋, 吴华星. 脂质组学在结直肠癌研究中的应用[J]. 实用肿瘤学杂志, 2019, 33(2): 179-192.
[3]	刘恒辰, 张新宇. Toll样受体信号通路作为结直肠癌潜在治疗靶点的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 188-192.
[4]	刘宏涛, 张彤彤综述, 刘雁军审校. 肥胖与结直肠癌发病机制的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 464-467.
[5]	王志, 刘忠卫, 曾雪芸, 隋明洁, 廖静怡, 李月欢, 黄卫东, 刘国祥. 基于EQ-5D-5L的结直肠癌癌前病变患者健康相关生命质量研究[J]. 实用肿瘤学杂志, 2018, 32(4): 320-326.
[6]	李文琪, 耿敬姝. RAS/RAF突变与MSI状态在结直肠癌治疗中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 371-376.
[7]	徐训政, 张好刚, 乔鹏飞, 王夫景. 循环肿瘤细胞检测的临床有效性和实用性分析[J]. 实用肿瘤学杂志, 2018, 32(2): 169-173.
[8]	张姗姗, 吴华星审校. 代谢组学在结直肠癌诊断中的应用[J]. 实用肿瘤学杂志, 2017, 31(6): 573-576.
[9]	孙丽娜, 赵晓迪综述, 卢瑗瑗, 王新审校. LncRNA与胃肠道肿瘤化疗耐药的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 448-453.
[10]	王东亮,戚宁,牟冠男,张月桂. 结直肠癌肿瘤微环境中调节性T细胞CD39、CD73亚群及二者双阳性亚群的临床意义[J]. 实用肿瘤学杂志, 2017, 31(4): 329-334.
[11]	郝小军，王传卓，赵相轩，辛鹤，刘兆玉. miR-34a对结肠癌细胞SW480增殖、迁移和侵袭能力的影响及机制探讨[J]. 实用肿瘤学杂志, 2017, 31(3): 193-198.
[12]	张明, 朱信强, 丁闯, 孔令永, 陈焰. 结直肠癌患者术后预后营养指数在预后评估中的应用[J]. 实用肿瘤学杂志, 2017, 31(2): 131-136.
[13]	苗大壮, 佟金学, 贾云鹤. 加速康复外科理念在腹腔镜辅助结直肠癌手术围手术期中的应用价值[J]. 实用肿瘤学杂志, 2017, 31(2): 137-141.
[14]	崔君鹏, 刘宝林. VDR基因FokI位点多态性与结直肠癌易感性之间关系的Meta分析[J]. 实用肿瘤学杂志, 2016, 30(5): 400-408.
[15]	罗斌,施奇惠,刘嘉湘综述,田建辉审校. 肺癌循环肿瘤细胞的临床意义[J]. 实用肿瘤学杂志, 2016, 30(4): 370-374.